CORD-19:ee0a7632371a08727d41e55aad7d621daeceef7d / 85490-85706 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T62374","span":{"begin":0,"end":216},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Whereas the JAK-2V617F allele has been implicated in several of the myeloproliferative disorders, a significant proportion of patients with primary myelofibrosis (MF), or thrombocythemia (ET) are JAK-2V617F negative."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T365","span":{"begin":0,"end":216},"obj":"Sentence"}],"text":"Whereas the JAK-2V617F allele has been implicated in several of the myeloproliferative disorders, a significant proportion of patients with primary myelofibrosis (MF), or thrombocythemia (ET) are JAK-2V617F negative."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T185","span":{"begin":68,"end":96},"obj":"Phenotype"},{"id":"T186","span":{"begin":148,"end":161},"obj":"Phenotype"},{"id":"T187","span":{"begin":163,"end":165},"obj":"Phenotype"},{"id":"T188","span":{"begin":171,"end":186},"obj":"Phenotype"}],"attributes":[{"id":"A185","pred":"hp_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/HP_0005547"},{"id":"A186","pred":"hp_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/HP_0011974"},{"id":"A187","pred":"hp_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/HP_0011974"},{"id":"A188","pred":"hp_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/HP_0001894"}],"text":"Whereas the JAK-2V617F allele has been implicated in several of the myeloproliferative disorders, a significant proportion of patients with primary myelofibrosis (MF), or thrombocythemia (ET) are JAK-2V617F negative."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T455","span":{"begin":68,"end":96},"obj":"Disease"},{"id":"T456","span":{"begin":140,"end":161},"obj":"Disease"},{"id":"T457","span":{"begin":148,"end":161},"obj":"Disease"},{"id":"T458","span":{"begin":163,"end":165},"obj":"Disease"},{"id":"T461","span":{"begin":171,"end":186},"obj":"Disease"},{"id":"T462","span":{"begin":188,"end":190},"obj":"Disease"},{"id":"T454","span":{"begin":68,"end":96},"obj":"Disease"},{"id":"T48911","span":{"begin":140,"end":161},"obj":"Disease"},{"id":"T20297","span":{"begin":148,"end":161},"obj":"Disease"},{"id":"T37443","span":{"begin":163,"end":165},"obj":"Disease"},{"id":"T460","span":{"begin":171,"end":186},"obj":"Disease"},{"id":"T49171","span":{"begin":188,"end":190},"obj":"Disease"}],"attributes":[{"id":"A455","pred":"mondo_id","subj":"T455","obj":"http://purl.obolibrary.org/obo/MONDO_0020076"},{"id":"A456","pred":"mondo_id","subj":"T456","obj":"http://purl.obolibrary.org/obo/MONDO_0009692"},{"id":"A457","pred":"mondo_id","subj":"T457","obj":"http://purl.obolibrary.org/obo/MONDO_0044903"},{"id":"A458","pred":"mondo_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/MONDO_0009691"},{"id":"A459","pred":"mondo_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/MONDO_0020481"},{"id":"A460","pred":"mondo_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/MONDO_0009692"},{"id":"A461","pred":"mondo_id","subj":"T461","obj":"http://purl.obolibrary.org/obo/MONDO_0019111"},{"id":"A462","pred":"mondo_id","subj":"T462","obj":"http://purl.obolibrary.org/obo/MONDO_0005029"},{"id":"A9725","pred":"mondo_id","subj":"T454","obj":"http://purl.obolibrary.org/obo/MONDO_0020076"},{"id":"A20876","pred":"mondo_id","subj":"T48911","obj":"http://purl.obolibrary.org/obo/MONDO_0009692"},{"id":"A40528","pred":"mondo_id","subj":"T20297","obj":"http://purl.obolibrary.org/obo/MONDO_0044903"},{"id":"A25622","pred":"mondo_id","subj":"T37443","obj":"http://purl.obolibrary.org/obo/MONDO_0009691"},{"id":"A65591","pred":"mondo_id","subj":"T37443","obj":"http://purl.obolibrary.org/obo/MONDO_0020481"},{"id":"A69657","pred":"mondo_id","subj":"T37443","obj":"http://purl.obolibrary.org/obo/MONDO_0009692"},{"id":"A5936","pred":"mondo_id","subj":"T460","obj":"http://purl.obolibrary.org/obo/MONDO_0019111"},{"id":"A25761","pred":"mondo_id","subj":"T49171","obj":"http://purl.obolibrary.org/obo/MONDO_0005029"}],"text":"Whereas the JAK-2V617F allele has been implicated in several of the myeloproliferative disorders, a significant proportion of patients with primary myelofibrosis (MF), or thrombocythemia (ET) are JAK-2V617F negative."}